Skip to content
2000
Volume 21, Issue 2
  • ISSN: 1871-529X
  • E-ISSN: 2212-4063

Abstract

After the outbreak of COVID-19, many novel drugs have been introduced to improve patients’ conditions. Remdesivir and Favipiravir are among the most common drugs used against SARS-CoV-2. Although promising, cardiovascular side effects of these drugs should be considered by physicians and nurses. In this study, we searched databases for assessing the cardiovascular side effects of Remdesivir and Favipiravir. It seems that despite the beneficial effects of these drugs, due to the cardiovascular complications of COVID-19 and cardiovascular side effects of these drugs, which can overlap with each other, the use of these drugs can be a challenging issue in the cardiovascular practice.

Loading

Article metrics loading...

/content/journals/chddt/10.2174/1871529X21666210812103535
2021-06-01
2025-11-06
Loading full text...

Full text loading...

/content/journals/chddt/10.2174/1871529X21666210812103535
Loading

  • Article Type:
    Letter
Keyword(s): cardiovascular; COVID-19; favipiravir; heart; Remdesivir; side effect
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test